Newswise — Rockville, Md. — The Association for Research in Vision and Ophthalmology is pleased to host three special sessions during the 2013 Annual Meeting (May 5 – 9) in Seattle, Wash. These sessions will take place at the Washington State Convention Center.
Results from the Age-Related Eye Disease Study 2 (AREDS2) from the National Eye InstituteFindings from a randomized, controlled clinical trial of lutein/zeaxanthin and omega-3 fatty acids for the treatment of age-related macular degeneration and cataractSunday, May 5, 2013, 4:15 – 5:15pm, Ballroom 6ABC
The results from this clinical trial will be published online in JAMA (the Journal of the American Medical Association) and JAMA Ophthalmology and embargoed until Sunday, May 5 at 7pm Eastern time to coincide with presentation at the ARVO 2013 Annual Meeting.
This session also will be streamed live. The livestream is free of charge, but advance registration is required. Please visit http://www.prolibraries.com/arvo/events/arvo2013/.
PresentersEmily Chew, MDTraci Clemons, PhDRonald Danis, MDJohn Paul SanGiovanni, ScD
With an introduction byPaul Sieving, MD, PhD, director, National Eye Institute
The Age-Related Eye Disease Study 2 (AREDS2) Research Team will present the results of the multi-centered randomized controlled clinical trial of oral supplementation with lutein/zeaxanthin (10 mg/2mg) and/or omega-3 long-chain polyunsaturated fatty acids (LCPUFAs-1 g) for the treatment of age-related macular degeneration (AMD) and cataract.
This multi-centered trial was conducted in 82 clinical sites in the U.S., in both academic and community-based centers with retinal specialists from 2006 to 2012, in 4,203 participants, aged 50 – 85.
Ranibizumab versus Bevacizumab: Results from the IVAN2 and GEFAL Trials Tuesday, May 7, 1 ‒ 2:30pm, Ballroom 6ESession moderator: Daniel F. Martin, MD
IVAN Trial Introduction: Usha Chakravarthy , MBBS, PhD, FARVOStudy Outcomes: Simon Harding, FRCOphth, MDIVAN Panel Discussion: Usha Chakravarthy, MBBS, PhD, FARVO; Simon Harding, FRCOphth, MD; Chris Rogers
GEFAL Study Overview: Laurent Kodjikian, MD, PhDGEFAL Panel Discussion: Eric Souied, MD, PhD; Laure Huot; Evelyne Decullier; Laurent KodjikianModerator: Daniel F. Martin, MD
Summary Panel Discussion: Comparative effectiveness of Ranibizumab versus Bevacizumab
NEI Audacious Goals Initiative in Vision Research and Blindness RehabilitationSunday, May 5, 12:15 – 1pm, Ballroom 6E
NEI Director Paul A. Sieving, MD, PhD, will describe development of the NEI Audacious Goals Initiative, announce the goals and high priority areas and discuss implementation.
For information or to register for the ARVO 2013 Annual Meeting, visit www.arvo.org/am.
# # #
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include over 12,000 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.
Website: www.arvo.org Twitter: www.twitter.com/#!/ARVOinfoFacebook: www.facebook.com/ARVOinfo
RSS